nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—BCHE—multiple sclerosis	0.477	1	CbGaD
Galantamine—BCHE—Triamcinolone—multiple sclerosis	0.0727	0.348	CbGbCtD
Galantamine—CYP2D6—Fingolimod—multiple sclerosis	0.0356	0.17	CbGbCtD
Galantamine—CYP3A4—Fingolimod—multiple sclerosis	0.0226	0.108	CbGbCtD
Galantamine—CHRNB3—pons—multiple sclerosis	0.0175	0.169	CbGeAlD
Galantamine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0146	0.0698	CbGbCtD
Galantamine—CYP3A4—Triamcinolone—multiple sclerosis	0.0111	0.0529	CbGbCtD
Galantamine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0106	0.0509	CbGbCtD
Galantamine—CYP3A4—Betamethasone—multiple sclerosis	0.00948	0.0454	CbGbCtD
Galantamine—CYP3A4—Prednisolone—multiple sclerosis	0.00936	0.0448	CbGbCtD
Galantamine—CYP3A4—Prednisone—multiple sclerosis	0.00883	0.0423	CbGbCtD
Galantamine—CYP2D6—Dexamethasone—multiple sclerosis	0.00867	0.0415	CbGbCtD
Galantamine—CYP3A4—Dexamethasone—multiple sclerosis	0.00552	0.0264	CbGbCtD
Galantamine—CHRNB3—brainstem—multiple sclerosis	0.00391	0.0377	CbGeAlD
Galantamine—CHRNA4—peripheral nervous system—multiple sclerosis	0.0035	0.0338	CbGeAlD
Galantamine—CHRNA6—brainstem—multiple sclerosis	0.00326	0.0315	CbGeAlD
Galantamine—CHRNA4—nerve—multiple sclerosis	0.00273	0.0263	CbGeAlD
Galantamine—CHRNB3—midbrain—multiple sclerosis	0.00249	0.024	CbGeAlD
Galantamine—CHRNA5—nervous system—multiple sclerosis	0.00225	0.0218	CbGeAlD
Galantamine—CHRNA5—central nervous system—multiple sclerosis	0.00217	0.021	CbGeAlD
Galantamine—CHRNG—medulla oblongata—multiple sclerosis	0.00214	0.0207	CbGeAlD
Galantamine—CHRNA6—midbrain—multiple sclerosis	0.00208	0.0201	CbGeAlD
Galantamine—CHRNB3—nervous system—multiple sclerosis	0.00205	0.0198	CbGeAlD
Galantamine—CHRNB3—central nervous system—multiple sclerosis	0.00197	0.019	CbGeAlD
Galantamine—CHRNG—midbrain—multiple sclerosis	0.00196	0.0189	CbGeAlD
Galantamine—CHRNB3—cerebellum—multiple sclerosis	0.00193	0.0186	CbGeAlD
Galantamine—CHRNA3—retina—multiple sclerosis	0.00175	0.0169	CbGeAlD
Galantamine—CHRNA5—brain—multiple sclerosis	0.00172	0.0166	CbGeAlD
Galantamine—CHRNA6—nervous system—multiple sclerosis	0.00171	0.0165	CbGeAlD
Galantamine—CHRNA6—central nervous system—multiple sclerosis	0.00164	0.0159	CbGeAlD
Galantamine—CHRNA6—cerebellum—multiple sclerosis	0.00161	0.0155	CbGeAlD
Galantamine—CHRNB3—brain—multiple sclerosis	0.00156	0.0151	CbGeAlD
Galantamine—CHRNB4—nervous system—multiple sclerosis	0.00155	0.015	CbGeAlD
Galantamine—CHRNB4—central nervous system—multiple sclerosis	0.00149	0.0144	CbGeAlD
Galantamine—CHRNB2—medulla oblongata—multiple sclerosis	0.00131	0.0126	CbGeAlD
Galantamine—CHRNA6—brain—multiple sclerosis	0.00131	0.0126	CbGeAlD
Galantamine—CHRNB2—midbrain—multiple sclerosis	0.00119	0.0115	CbGeAlD
Galantamine—CHRNB4—brain—multiple sclerosis	0.00119	0.0115	CbGeAlD
Galantamine—CHRNA4—brainstem—multiple sclerosis	0.00117	0.0113	CbGeAlD
Galantamine—CHRNB2—spinal cord—multiple sclerosis	0.00116	0.0112	CbGeAlD
Galantamine—CHRNA7—retina—multiple sclerosis	0.00114	0.0111	CbGeAlD
Galantamine—CHRNB1—medulla oblongata—multiple sclerosis	0.0011	0.0106	CbGeAlD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00106	0.0327	CbGpPWpGaD
Galantamine—CHRNB1—midbrain—multiple sclerosis	0.001	0.00967	CbGeAlD
Galantamine—CHRNB2—nervous system—multiple sclerosis	0.000981	0.00948	CbGeAlD
Galantamine—CHRNB1—spinal cord—multiple sclerosis	0.000977	0.00943	CbGeAlD
Galantamine—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.000967	0.0297	CbGpPWpGaD
Galantamine—CHRNA3—nervous system—multiple sclerosis	0.000952	0.00919	CbGeAlD
Galantamine—ACHE—medulla oblongata—multiple sclerosis	0.00095	0.00917	CbGeAlD
Galantamine—CHRNB2—central nervous system—multiple sclerosis	0.000945	0.00912	CbGeAlD
Galantamine—CHRNB2—cerebellum—multiple sclerosis	0.000923	0.00892	CbGeAlD
Galantamine—CHRNA3—central nervous system—multiple sclerosis	0.000916	0.00885	CbGeAlD
Galantamine—CHRNA9—Neuronal System—KCNA3—multiple sclerosis	0.000915	0.0281	CbGpPWpGaD
Galantamine—CHRNA3—cerebellum—multiple sclerosis	0.000895	0.00865	CbGeAlD
Galantamine—CHRNA2—nervous system—multiple sclerosis	0.000885	0.00854	CbGeAlD
Galantamine—ACHE—midbrain—multiple sclerosis	0.000868	0.00838	CbGeAlD
Galantamine—CHRNA2—central nervous system—multiple sclerosis	0.000852	0.00823	CbGeAlD
Galantamine—ACHE—spinal cord—multiple sclerosis	0.000847	0.00818	CbGeAlD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000837	0.0257	CbGpPWpGaD
Galantamine—CHRNA2—cerebellum—multiple sclerosis	0.000832	0.00804	CbGeAlD
Galantamine—CHRNA1—brain—multiple sclerosis	0.000815	0.00787	CbGeAlD
Galantamine—CHRNB3—Neuronal System—KCNA3—multiple sclerosis	0.0008	0.0246	CbGpPWpGaD
Galantamine—CHRNB1—cerebellum—multiple sclerosis	0.000775	0.00748	CbGeAlD
Galantamine—CHRFAM7A—nervous system—multiple sclerosis	0.00077	0.00743	CbGeAlD
Galantamine—CHRNA5—Neuronal System—KCNA3—multiple sclerosis	0.000758	0.0233	CbGpPWpGaD
Galantamine—CHRNB2—brain—multiple sclerosis	0.00075	0.00724	CbGeAlD
Galantamine—CHRNA4—midbrain—multiple sclerosis	0.000746	0.0072	CbGeAlD
Galantamine—CHRFAM7A—central nervous system—multiple sclerosis	0.000741	0.00716	CbGeAlD
Galantamine—CHRNA4—spinal cord—multiple sclerosis	0.000728	0.00703	CbGeAlD
Galantamine—CHRNA3—brain—multiple sclerosis	0.000727	0.00702	CbGeAlD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000726	0.0223	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—KCNA3—multiple sclerosis	0.000723	0.0222	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—KCNA3—multiple sclerosis	0.00068	0.0209	CbGpPWpGaD
Galantamine—CHRNA2—brain—multiple sclerosis	0.000676	0.00653	CbGeAlD
Galantamine—ACHE—cerebellum—multiple sclerosis	0.000672	0.00649	CbGeAlD
Galantamine—BCHE—brainstem—multiple sclerosis	0.000669	0.00647	CbGeAlD
Galantamine—CHRNB1—brain—multiple sclerosis	0.000629	0.00608	CbGeAlD
Galantamine—CHRNA7—nervous system—multiple sclerosis	0.000622	0.006	CbGeAlD
Galantamine—CHRNA4—nervous system—multiple sclerosis	0.000613	0.00592	CbGeAlD
Galantamine—CHRNA7—central nervous system—multiple sclerosis	0.000598	0.00578	CbGeAlD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000592	0.0182	CbGpPWpGaD
Galantamine—CHRNA4—central nervous system—multiple sclerosis	0.00059	0.0057	CbGeAlD
Galantamine—CHRFAM7A—brain—multiple sclerosis	0.000588	0.00568	CbGeAlD
Galantamine—CHRNA4—cerebellum—multiple sclerosis	0.000577	0.00557	CbGeAlD
Galantamine—CHRNA6—Neuronal System—KCNA3—multiple sclerosis	0.000575	0.0177	CbGpPWpGaD
Galantamine—ACHE—brain—multiple sclerosis	0.000546	0.00527	CbGeAlD
Galantamine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—BCHE—multiple sclerosis	0.000529	0.0162	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—KCNA3—multiple sclerosis	0.000506	0.0155	CbGpPWpGaD
Galantamine—ACHE—Synthesis of PC—BCHE—multiple sclerosis	0.000484	0.0149	CbGpPWpGaD
Galantamine—CHRNA7—brain—multiple sclerosis	0.000475	0.00459	CbGeAlD
Galantamine—CHRNA4—brain—multiple sclerosis	0.000469	0.00453	CbGeAlD
Galantamine—BCHE—medulla oblongata—multiple sclerosis	0.000467	0.00451	CbGeAlD
Galantamine—ACHE—ATF-2 transcription factor network—IL23A—multiple sclerosis	0.000449	0.0138	CbGpPWpGaD
Galantamine—CYP2D6—brainstem—multiple sclerosis	0.000444	0.00428	CbGeAlD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000441	0.0136	CbGpPWpGaD
Galantamine—BCHE—midbrain—multiple sclerosis	0.000427	0.00412	CbGeAlD
Galantamine—BCHE—spinal cord—multiple sclerosis	0.000416	0.00402	CbGeAlD
Galantamine—CHRND—Neuronal System—KCNA3—multiple sclerosis	0.000402	0.0124	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—KCNA3—multiple sclerosis	0.000398	0.0122	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—KCNA3—multiple sclerosis	0.000364	0.0112	CbGpPWpGaD
Galantamine—BCHE—nervous system—multiple sclerosis	0.000351	0.00339	CbGeAlD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000348	0.0107	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—KCNA3—multiple sclerosis	0.000346	0.0106	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—KCNA3—multiple sclerosis	0.000342	0.0105	CbGpPWpGaD
Galantamine—BCHE—central nervous system—multiple sclerosis	0.000338	0.00326	CbGeAlD
Galantamine—CHRNA9—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000335	0.0103	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000335	0.0103	CbGpPWpGaD
Galantamine—BCHE—cerebellum—multiple sclerosis	0.00033	0.00319	CbGeAlD
Galantamine—CHRNA2—Neuronal System—KCNA3—multiple sclerosis	0.000325	0.00998	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000302	0.00926	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000293	0.009	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—STAT3—multiple sclerosis	0.000284	0.00874	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—KCNA3—multiple sclerosis	0.000282	0.00866	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000278	0.00853	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—SLC30A7—multiple sclerosis	0.000273	0.0084	CbGpPWpGaD
Galantamine—BCHE—brain—multiple sclerosis	0.000268	0.00259	CbGeAlD
Galantamine—CHRNG—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000265	0.00813	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000263	0.00809	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—MAPK1—multiple sclerosis	0.000259	0.00794	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—SELE—multiple sclerosis	0.000258	0.00792	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—BCHE—multiple sclerosis	0.000257	0.00788	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000249	0.00765	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000246	0.00755	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—SLC30A7—multiple sclerosis	0.000244	0.00749	CbGpPWpGaD
Galantamine—CYP3A4—nervous system—multiple sclerosis	0.000236	0.00228	CbGeAlD
Galantamine—CYP2D6—nervous system—multiple sclerosis	0.000232	0.00224	CbGeAlD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000229	0.00702	CbGpPWpGaD
Galantamine—CYP3A4—central nervous system—multiple sclerosis	0.000227	0.0022	CbGeAlD
Galantamine—CHRNB3—Neuronal System—BCHE—multiple sclerosis	0.000224	0.00689	CbGpPWpGaD
Galantamine—CYP2D6—central nervous system—multiple sclerosis	0.000224	0.00216	CbGeAlD
Galantamine—CYP2D6—cerebellum—multiple sclerosis	0.000219	0.00211	CbGeAlD
Galantamine—CHRNA5—Neuronal System—BCHE—multiple sclerosis	0.000213	0.00653	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.00021	0.00646	CbGpPWpGaD
Galantamine—ACHE—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000208	0.00638	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—BCHE—multiple sclerosis	0.000203	0.00623	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—KCNA3—multiple sclerosis	0.000201	0.00618	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—BCHE—multiple sclerosis	0.000191	0.00586	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000187	0.00575	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000187	0.00575	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000186	0.00572	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000185	0.00569	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000182	0.00558	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000182	0.00558	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—KCNA3—multiple sclerosis	0.000179	0.00551	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000179	0.00551	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000179	0.00551	CbGpPWpGaD
Galantamine—CYP2D6—brain—multiple sclerosis	0.000178	0.00172	CbGeAlD
Galantamine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000173	0.000977	CcSEcCtD
Galantamine—Myalgia—Methylprednisolone—multiple sclerosis	0.000173	0.000977	CcSEcCtD
Galantamine—Eye disorder—Prednisone—multiple sclerosis	0.000173	0.000976	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000173	0.00532	CbGpPWpGaD
Galantamine—Anxiety—Methylprednisolone—multiple sclerosis	0.000173	0.000974	CcSEcCtD
Galantamine—Rash—Azathioprine—multiple sclerosis	0.000172	0.000971	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000172	0.000971	CcSEcCtD
Galantamine—Dermatitis—Azathioprine—multiple sclerosis	0.000172	0.00097	CcSEcCtD
Galantamine—Depression—Methotrexate—multiple sclerosis	0.000172	0.000969	CcSEcCtD
Galantamine—Flushing—Prednisone—multiple sclerosis	0.000172	0.000969	CcSEcCtD
Galantamine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000172	0.000969	CcSEcCtD
Galantamine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000172	0.000969	CcSEcCtD
Galantamine—Discomfort—Triamcinolone—multiple sclerosis	0.000172	0.000968	CcSEcCtD
Galantamine—Discomfort—Methylprednisolone—multiple sclerosis	0.000171	0.000966	CcSEcCtD
Galantamine—Headache—Azathioprine—multiple sclerosis	0.000171	0.000965	CcSEcCtD
Galantamine—Dry mouth—Triamcinolone—multiple sclerosis	0.00017	0.000958	CcSEcCtD
Galantamine—Renal failure—Methotrexate—multiple sclerosis	0.00017	0.000956	CcSEcCtD
Galantamine—Angiopathy—Prednisone—multiple sclerosis	0.000168	0.000948	CcSEcCtD
Galantamine—Confusional state—Methylprednisolone—multiple sclerosis	0.000168	0.000945	CcSEcCtD
Galantamine—Immune system disorder—Prednisone—multiple sclerosis	0.000167	0.000943	CcSEcCtD
Galantamine—Malaise—Dexamethasone—multiple sclerosis	0.000167	0.000941	CcSEcCtD
Galantamine—Malaise—Betamethasone—multiple sclerosis	0.000167	0.000941	CcSEcCtD
Galantamine—Vertigo—Betamethasone—multiple sclerosis	0.000166	0.000938	CcSEcCtD
Galantamine—Vertigo—Dexamethasone—multiple sclerosis	0.000166	0.000938	CcSEcCtD
Galantamine—Syncope—Dexamethasone—multiple sclerosis	0.000166	0.000936	CcSEcCtD
Galantamine—Syncope—Betamethasone—multiple sclerosis	0.000166	0.000936	CcSEcCtD
Galantamine—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000166	0.00509	CbGpPWpGaD
Galantamine—Arrhythmia—Prednisone—multiple sclerosis	0.000166	0.000933	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000165	0.00507	CbGpPWpGaD
Galantamine—Haematuria—Methotrexate—multiple sclerosis	0.000165	0.000927	CcSEcCtD
Galantamine—Shock—Triamcinolone—multiple sclerosis	0.000164	0.000924	CcSEcCtD
Galantamine—Insomnia—Prednisolone—multiple sclerosis	0.000164	0.000924	CcSEcCtD
Galantamine—Shock—Methylprednisolone—multiple sclerosis	0.000164	0.000922	CcSEcCtD
Galantamine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000163	0.00092	CcSEcCtD
Galantamine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000163	0.000919	CcSEcCtD
Galantamine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000163	0.000918	CcSEcCtD
Galantamine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000163	0.000918	CcSEcCtD
Galantamine—Epistaxis—Methotrexate—multiple sclerosis	0.000163	0.000917	CcSEcCtD
Galantamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000163	0.000917	CcSEcCtD
Galantamine—Paraesthesia—Prednisolone—multiple sclerosis	0.000163	0.000917	CcSEcCtD
Galantamine—Tachycardia—Triamcinolone—multiple sclerosis	0.000163	0.000916	CcSEcCtD
Galantamine—Mental disorder—Prednisone—multiple sclerosis	0.000162	0.000915	CcSEcCtD
Galantamine—Nausea—Azathioprine—multiple sclerosis	0.000162	0.000915	CcSEcCtD
Galantamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000162	0.000914	CcSEcCtD
Galantamine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000162	0.00091	CcSEcCtD
Galantamine—Malnutrition—Prednisone—multiple sclerosis	0.000161	0.000909	CcSEcCtD
Galantamine—CHRNA6—Neuronal System—BCHE—multiple sclerosis	0.000161	0.00495	CbGpPWpGaD
Galantamine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000161	0.000908	CcSEcCtD
Galantamine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000161	0.000906	CcSEcCtD
Galantamine—Convulsion—Betamethasone—multiple sclerosis	0.000161	0.000905	CcSEcCtD
Galantamine—Convulsion—Dexamethasone—multiple sclerosis	0.000161	0.000905	CcSEcCtD
Galantamine—Hypertension—Dexamethasone—multiple sclerosis	0.00016	0.000901	CcSEcCtD
Galantamine—Hypertension—Betamethasone—multiple sclerosis	0.00016	0.000901	CcSEcCtD
Galantamine—Asthenia—Mitoxantrone—multiple sclerosis	0.000158	0.000893	CcSEcCtD
Galantamine—Myalgia—Betamethasone—multiple sclerosis	0.000158	0.000889	CcSEcCtD
Galantamine—Myalgia—Dexamethasone—multiple sclerosis	0.000158	0.000889	CcSEcCtD
Galantamine—Anxiety—Dexamethasone—multiple sclerosis	0.000157	0.000886	CcSEcCtD
Galantamine—Anxiety—Betamethasone—multiple sclerosis	0.000157	0.000886	CcSEcCtD
Galantamine—Discomfort—Betamethasone—multiple sclerosis	0.000156	0.000878	CcSEcCtD
Galantamine—Discomfort—Dexamethasone—multiple sclerosis	0.000156	0.000878	CcSEcCtD
Galantamine—Haemoglobin—Methotrexate—multiple sclerosis	0.000156	0.000877	CcSEcCtD
Galantamine—Hypotension—Methylprednisolone—multiple sclerosis	0.000155	0.000875	CcSEcCtD
Galantamine—Haemorrhage—Methotrexate—multiple sclerosis	0.000155	0.000873	CcSEcCtD
Galantamine—Hepatitis—Methotrexate—multiple sclerosis	0.000155	0.000873	CcSEcCtD
Galantamine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000153	0.000862	CcSEcCtD
Galantamine—Vision blurred—Prednisone—multiple sclerosis	0.000152	0.000857	CcSEcCtD
Galantamine—Urethral disorder—Methotrexate—multiple sclerosis	0.000152	0.000856	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000152	0.000856	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000151	0.000854	CcSEcCtD
Galantamine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000151	0.000852	CcSEcCtD
Galantamine—Insomnia—Triamcinolone—multiple sclerosis	0.000151	0.000849	CcSEcCtD
Galantamine—Insomnia—Methylprednisolone—multiple sclerosis	0.00015	0.000847	CcSEcCtD
Galantamine—Ill-defined disorder—Prednisone—multiple sclerosis	0.00015	0.000844	CcSEcCtD
Galantamine—Paraesthesia—Triamcinolone—multiple sclerosis	0.00015	0.000843	CcSEcCtD
Galantamine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000149	0.000841	CcSEcCtD
Galantamine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000149	0.000841	CcSEcCtD
Galantamine—Visual impairment—Methotrexate—multiple sclerosis	0.000149	0.000841	CcSEcCtD
Galantamine—Anaemia—Prednisone—multiple sclerosis	0.000149	0.00084	CcSEcCtD
Galantamine—Shock—Dexamethasone—multiple sclerosis	0.000149	0.000838	CcSEcCtD
Galantamine—Shock—Betamethasone—multiple sclerosis	0.000149	0.000838	CcSEcCtD
Galantamine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000148	0.000836	CcSEcCtD
Galantamine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000148	0.000836	CcSEcCtD
Galantamine—Agitation—Prednisone—multiple sclerosis	0.000148	0.000835	CcSEcCtD
Galantamine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000148	0.000834	CcSEcCtD
Galantamine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000148	0.000834	CcSEcCtD
Galantamine—Tachycardia—Betamethasone—multiple sclerosis	0.000148	0.000832	CcSEcCtD
Galantamine—Tachycardia—Dexamethasone—multiple sclerosis	0.000148	0.000832	CcSEcCtD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000147	0.00453	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000147	0.00453	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000147	0.00452	CbGpPWpGaD
Galantamine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000147	0.000827	CcSEcCtD
Galantamine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000146	0.000825	CcSEcCtD
Galantamine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000146	0.000824	CcSEcCtD
Galantamine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000146	0.000824	CcSEcCtD
Galantamine—ACHE—Peptide hormone metabolism—BCHE—multiple sclerosis	0.000146	0.00448	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000146	0.00448	CbGpPWpGaD
Galantamine—Malaise—Prednisone—multiple sclerosis	0.000145	0.00082	CcSEcCtD
Galantamine—Vertigo—Prednisone—multiple sclerosis	0.000145	0.000817	CcSEcCtD
Galantamine—Eye disorder—Methotrexate—multiple sclerosis	0.000145	0.000816	CcSEcCtD
Galantamine—Syncope—Prednisone—multiple sclerosis	0.000145	0.000815	CcSEcCtD
Galantamine—Tinnitus—Methotrexate—multiple sclerosis	0.000144	0.000814	CcSEcCtD
Galantamine—Anorexia—Dexamethasone—multiple sclerosis	0.000144	0.000812	CcSEcCtD
Galantamine—Anorexia—Betamethasone—multiple sclerosis	0.000144	0.000812	CcSEcCtD
Galantamine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000144	0.00081	CcSEcCtD
Galantamine—Fatigue—Triamcinolone—multiple sclerosis	0.000144	0.00081	CcSEcCtD
Galantamine—Fatigue—Methylprednisolone—multiple sclerosis	0.000143	0.000808	CcSEcCtD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—STAT3—multiple sclerosis	0.000143	0.0044	CbGpPWpGaD
Galantamine—ACHE—Glycerophospholipid biosynthesis—BCHE—multiple sclerosis	0.000142	0.00436	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—BCHE—multiple sclerosis	0.000142	0.00436	CbGpPWpGaD
Galantamine—Loss of consciousness—Prednisone—multiple sclerosis	0.000142	0.000799	CcSEcCtD
Galantamine—Hypotension—Dexamethasone—multiple sclerosis	0.000141	0.000796	CcSEcCtD
Galantamine—Hypotension—Betamethasone—multiple sclerosis	0.000141	0.000796	CcSEcCtD
Galantamine—Angiopathy—Methotrexate—multiple sclerosis	0.000141	0.000792	CcSEcCtD
Galantamine—Vomiting—Mitoxantrone—multiple sclerosis	0.00014	0.000791	CcSEcCtD
Galantamine—Immune system disorder—Methotrexate—multiple sclerosis	0.00014	0.000788	CcSEcCtD
Galantamine—Convulsion—Prednisone—multiple sclerosis	0.00014	0.000788	CcSEcCtD
Galantamine—Hypertension—Prednisone—multiple sclerosis	0.000139	0.000785	CcSEcCtD
Galantamine—Rash—Mitoxantrone—multiple sclerosis	0.000139	0.000785	CcSEcCtD
Galantamine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000139	0.000784	CcSEcCtD
Galantamine—Headache—Mitoxantrone—multiple sclerosis	0.000138	0.00078	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000138	0.000776	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000138	0.000776	CcSEcCtD
Galantamine—Myalgia—Prednisone—multiple sclerosis	0.000137	0.000774	CcSEcCtD
Galantamine—Arthralgia—Prednisone—multiple sclerosis	0.000137	0.000774	CcSEcCtD
Galantamine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000137	0.000774	CcSEcCtD
Galantamine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000137	0.000772	CcSEcCtD
Galantamine—Anxiety—Prednisone—multiple sclerosis	0.000137	0.000771	CcSEcCtD
Galantamine—Insomnia—Betamethasone—multiple sclerosis	0.000137	0.000771	CcSEcCtD
Galantamine—Insomnia—Dexamethasone—multiple sclerosis	0.000137	0.000771	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000136	0.000769	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000136	0.00419	CbGpPWpGaD
Galantamine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000136	0.000766	CcSEcCtD
Galantamine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000136	0.000765	CcSEcCtD
Galantamine—Paraesthesia—Betamethasone—multiple sclerosis	0.000136	0.000765	CcSEcCtD
Galantamine—Discomfort—Prednisone—multiple sclerosis	0.000136	0.000765	CcSEcCtD
Galantamine—Mental disorder—Methotrexate—multiple sclerosis	0.000136	0.000765	CcSEcCtD
Galantamine—Malnutrition—Methotrexate—multiple sclerosis	0.000135	0.00076	CcSEcCtD
Galantamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000134	0.000752	CcSEcCtD
Galantamine—CHRNA3—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000133	0.0041	CbGpPWpGaD
Galantamine—Dyspepsia—Betamethasone—multiple sclerosis	0.000133	0.00075	CcSEcCtD
Galantamine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000133	0.00075	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000133	0.00408	CbGpPWpGaD
Galantamine—Dysgeusia—Methotrexate—multiple sclerosis	0.000132	0.000744	CcSEcCtD
Galantamine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000132	0.000742	CcSEcCtD
Galantamine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000131	0.000741	CcSEcCtD
Galantamine—Decreased appetite—Betamethasone—multiple sclerosis	0.000131	0.000741	CcSEcCtD
Galantamine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000131	0.000741	CcSEcCtD
Galantamine—Nausea—Mitoxantrone—multiple sclerosis	0.000131	0.000739	CcSEcCtD
Galantamine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000131	0.000736	CcSEcCtD
Galantamine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000131	0.000736	CcSEcCtD
Galantamine—Back pain—Methotrexate—multiple sclerosis	0.00013	0.000735	CcSEcCtD
Galantamine—Fatigue—Betamethasone—multiple sclerosis	0.00013	0.000735	CcSEcCtD
Galantamine—Fatigue—Dexamethasone—multiple sclerosis	0.00013	0.000735	CcSEcCtD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.00013	0.004	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.00013	0.004	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—MAPK1—multiple sclerosis	0.00013	0.004	CbGpPWpGaD
Galantamine—Shock—Prednisone—multiple sclerosis	0.00013	0.00073	CcSEcCtD
Galantamine—Nervous system disorder—Prednisone—multiple sclerosis	0.000129	0.000728	CcSEcCtD
Galantamine—Tachycardia—Prednisone—multiple sclerosis	0.000129	0.000724	CcSEcCtD
Galantamine—Skin disorder—Prednisone—multiple sclerosis	0.000128	0.000721	CcSEcCtD
Galantamine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000127	0.000717	CcSEcCtD
Galantamine—Vision blurred—Methotrexate—multiple sclerosis	0.000127	0.000716	CcSEcCtD
Galantamine—CHRNA7—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000127	0.00389	CbGpPWpGaD
Galantamine—Anorexia—Prednisone—multiple sclerosis	0.000126	0.000707	CcSEcCtD
Galantamine—CHRNA1—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000125	0.00385	CbGpPWpGaD
Galantamine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000125	0.000705	CcSEcCtD
Galantamine—Anaemia—Methotrexate—multiple sclerosis	0.000125	0.000702	CcSEcCtD
Galantamine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000125	0.000702	CcSEcCtD
Galantamine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000125	0.000702	CcSEcCtD
Galantamine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000124	0.000697	CcSEcCtD
Galantamine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000124	0.000697	CcSEcCtD
Galantamine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000123	0.000692	CcSEcCtD
Galantamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000123	0.00069	CcSEcCtD
Galantamine—ACHE—Monoamine Transport—IL1B—multiple sclerosis	0.000122	0.00376	CbGpPWpGaD
Galantamine—Malaise—Methotrexate—multiple sclerosis	0.000122	0.000685	CcSEcCtD
Galantamine—Vertigo—Methotrexate—multiple sclerosis	0.000121	0.000683	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—FAS—multiple sclerosis	0.000121	0.00371	CbGpPWpGaD
Galantamine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00012	0.000676	CcSEcCtD
Galantamine—Dizziness—Prednisolone—multiple sclerosis	0.00012	0.000675	CcSEcCtD
Galantamine—Asthenia—Triamcinolone—multiple sclerosis	0.00012	0.000674	CcSEcCtD
Galantamine—Abdominal pain—Betamethasone—multiple sclerosis	0.00012	0.000674	CcSEcCtD
Galantamine—Body temperature increased—Dexamethasone—multiple sclerosis	0.00012	0.000674	CcSEcCtD
Galantamine—Abdominal pain—Dexamethasone—multiple sclerosis	0.00012	0.000674	CcSEcCtD
Galantamine—Body temperature increased—Betamethasone—multiple sclerosis	0.00012	0.000674	CcSEcCtD
Galantamine—Asthenia—Methylprednisolone—multiple sclerosis	0.000119	0.000672	CcSEcCtD
Galantamine—Insomnia—Prednisone—multiple sclerosis	0.000119	0.000671	CcSEcCtD
Galantamine—CHRNA2—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000119	0.00366	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000119	0.00365	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000119	0.00365	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000118	0.00363	CbGpPWpGaD
Galantamine—Paraesthesia—Prednisone—multiple sclerosis	0.000118	0.000666	CcSEcCtD
Galantamine—Cough—Methotrexate—multiple sclerosis	0.000118	0.000663	CcSEcCtD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000117	0.0036	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000117	0.0036	CbGpPWpGaD
Galantamine—Convulsion—Methotrexate—multiple sclerosis	0.000117	0.000658	CcSEcCtD
Galantamine—Dyspepsia—Prednisone—multiple sclerosis	0.000116	0.000653	CcSEcCtD
Galantamine—Myalgia—Methotrexate—multiple sclerosis	0.000115	0.000647	CcSEcCtD
Galantamine—Arthralgia—Methotrexate—multiple sclerosis	0.000115	0.000647	CcSEcCtD
Galantamine—Chest pain—Methotrexate—multiple sclerosis	0.000115	0.000647	CcSEcCtD
Galantamine—Decreased appetite—Prednisone—multiple sclerosis	0.000114	0.000645	CcSEcCtD
Galantamine—Rash—Prednisolone—multiple sclerosis	0.000114	0.000644	CcSEcCtD
Galantamine—Dermatitis—Prednisolone—multiple sclerosis	0.000114	0.000643	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000114	0.000642	CcSEcCtD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.000114	0.0035	CbGpPWpGaD
Galantamine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000114	0.000641	CcSEcCtD
Galantamine—Fatigue—Prednisone—multiple sclerosis	0.000114	0.00064	CcSEcCtD
Galantamine—Headache—Prednisolone—multiple sclerosis	0.000114	0.00064	CcSEcCtD
Galantamine—Discomfort—Methotrexate—multiple sclerosis	0.000113	0.000639	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000113	0.00347	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—BCHE—multiple sclerosis	0.000113	0.00347	CbGpPWpGaD
Galantamine—Constipation—Prednisone—multiple sclerosis	0.000113	0.000635	CcSEcCtD
Galantamine—CHRNB4—Neuronal System—BCHE—multiple sclerosis	0.000112	0.00343	CbGpPWpGaD
Galantamine—Confusional state—Methotrexate—multiple sclerosis	0.000111	0.000625	CcSEcCtD
Galantamine—Dizziness—Triamcinolone—multiple sclerosis	0.00011	0.000621	CcSEcCtD
Galantamine—Dizziness—Methylprednisolone—multiple sclerosis	0.00011	0.00062	CcSEcCtD
Galantamine—Feeling abnormal—Prednisone—multiple sclerosis	0.000109	0.000611	CcSEcCtD
Galantamine—Asthenia—Dexamethasone—multiple sclerosis	0.000108	0.000611	CcSEcCtD
Galantamine—Asthenia—Betamethasone—multiple sclerosis	0.000108	0.000611	CcSEcCtD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.000108	0.00332	CbGpPWpGaD
Galantamine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000108	0.000608	CcSEcCtD
Galantamine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000108	0.000607	CcSEcCtD
Galantamine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000108	0.000607	CcSEcCtD
Galantamine—Nausea—Prednisolone—multiple sclerosis	0.000108	0.000607	CcSEcCtD
Galantamine—Skin disorder—Methotrexate—multiple sclerosis	0.000107	0.000602	CcSEcCtD
Galantamine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000107	0.00327	CbGpPWpGaD
Galantamine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000106	0.000599	CcSEcCtD
Galantamine—Vomiting—Triamcinolone—multiple sclerosis	0.000106	0.000597	CcSEcCtD
Galantamine—Vomiting—Methylprednisolone—multiple sclerosis	0.000106	0.000596	CcSEcCtD
Galantamine—Rash—Triamcinolone—multiple sclerosis	0.000105	0.000592	CcSEcCtD
Galantamine—Dermatitis—Triamcinolone—multiple sclerosis	0.000105	0.000592	CcSEcCtD
Galantamine—Anorexia—Methotrexate—multiple sclerosis	0.000105	0.000591	CcSEcCtD
Galantamine—Rash—Methylprednisolone—multiple sclerosis	0.000105	0.000591	CcSEcCtD
Galantamine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000105	0.00059	CcSEcCtD
Galantamine—Headache—Triamcinolone—multiple sclerosis	0.000104	0.000588	CcSEcCtD
Galantamine—Headache—Methylprednisolone—multiple sclerosis	0.000104	0.000587	CcSEcCtD
Galantamine—Body temperature increased—Prednisone—multiple sclerosis	0.000104	0.000587	CcSEcCtD
Galantamine—Abdominal pain—Prednisone—multiple sclerosis	0.000104	0.000587	CcSEcCtD
Galantamine—Diarrhoea—Betamethasone—multiple sclerosis	0.000103	0.000583	CcSEcCtD
Galantamine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000103	0.000583	CcSEcCtD
Galantamine—CHRNA4—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000103	0.00317	CbGpPWpGaD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.000103	0.00316	CbGpPWpGaD
Galantamine—Hypotension—Methotrexate—multiple sclerosis	0.000103	0.000579	CcSEcCtD
Galantamine—CHRNA3—Neuronal System—BCHE—multiple sclerosis	0.000102	0.00314	CbGpPWpGaD
Galantamine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.0001	0.000565	CcSEcCtD
Galantamine—Dizziness—Betamethasone—multiple sclerosis	0.0001	0.000563	CcSEcCtD
Galantamine—Dizziness—Dexamethasone—multiple sclerosis	0.0001	0.000563	CcSEcCtD
Galantamine—Insomnia—Methotrexate—multiple sclerosis	9.95e-05	0.000561	CcSEcCtD
Galantamine—ACHE—Phospholipid metabolism—BCHE—multiple sclerosis	9.91e-05	0.00304	CbGpPWpGaD
Galantamine—Nausea—Triamcinolone—multiple sclerosis	9.9e-05	0.000558	CcSEcCtD
Galantamine—Paraesthesia—Methotrexate—multiple sclerosis	9.88e-05	0.000557	CcSEcCtD
Galantamine—Nausea—Methylprednisolone—multiple sclerosis	9.88e-05	0.000557	CcSEcCtD
Galantamine—CHRNA9—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	9.79e-05	0.00301	CbGpPWpGaD
Galantamine—Somnolence—Methotrexate—multiple sclerosis	9.78e-05	0.000551	CcSEcCtD
Galantamine—Hypersensitivity—Prednisone—multiple sclerosis	9.7e-05	0.000547	CcSEcCtD
Galantamine—CHRNA7—Neuronal System—BCHE—multiple sclerosis	9.7e-05	0.00298	CbGpPWpGaD
Galantamine—Dyspepsia—Methotrexate—multiple sclerosis	9.69e-05	0.000546	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	9.68e-05	0.00297	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	9.64e-05	0.00296	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	9.63e-05	0.00296	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	9.63e-05	0.00296	CbGpPWpGaD
Galantamine—Vomiting—Dexamethasone—multiple sclerosis	9.61e-05	0.000542	CcSEcCtD
Galantamine—Vomiting—Betamethasone—multiple sclerosis	9.61e-05	0.000542	CcSEcCtD
Galantamine—CHRNA1—Neuronal System—BCHE—multiple sclerosis	9.6e-05	0.00295	CbGpPWpGaD
Galantamine—Decreased appetite—Methotrexate—multiple sclerosis	9.57e-05	0.000539	CcSEcCtD
Galantamine—Rash—Dexamethasone—multiple sclerosis	9.53e-05	0.000537	CcSEcCtD
Galantamine—Rash—Betamethasone—multiple sclerosis	9.53e-05	0.000537	CcSEcCtD
Galantamine—Dermatitis—Dexamethasone—multiple sclerosis	9.52e-05	0.000537	CcSEcCtD
Galantamine—Dermatitis—Betamethasone—multiple sclerosis	9.52e-05	0.000537	CcSEcCtD
Galantamine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.5e-05	0.000535	CcSEcCtD
Galantamine—Fatigue—Methotrexate—multiple sclerosis	9.49e-05	0.000535	CcSEcCtD
Galantamine—Headache—Dexamethasone—multiple sclerosis	9.47e-05	0.000534	CcSEcCtD
Galantamine—Headache—Betamethasone—multiple sclerosis	9.47e-05	0.000534	CcSEcCtD
Galantamine—Asthenia—Prednisone—multiple sclerosis	9.45e-05	0.000532	CcSEcCtD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL10—multiple sclerosis	9.2e-05	0.00283	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—BCHE—multiple sclerosis	9.12e-05	0.0028	CbGpPWpGaD
Galantamine—Feeling abnormal—Methotrexate—multiple sclerosis	9.07e-05	0.000511	CcSEcCtD
Galantamine—Diarrhoea—Prednisone—multiple sclerosis	9.01e-05	0.000508	CcSEcCtD
Galantamine—Gastrointestinal pain—Methotrexate—multiple sclerosis	9e-05	0.000507	CcSEcCtD
Galantamine—Nausea—Betamethasone—multiple sclerosis	8.98e-05	0.000506	CcSEcCtD
Galantamine—Nausea—Dexamethasone—multiple sclerosis	8.98e-05	0.000506	CcSEcCtD
Galantamine—ACHE—Monoamine Transport—TNF—multiple sclerosis	8.87e-05	0.00273	CbGpPWpGaD
Galantamine—Dizziness—Prednisone—multiple sclerosis	8.71e-05	0.000491	CcSEcCtD
Galantamine—Abdominal pain—Methotrexate—multiple sclerosis	8.7e-05	0.00049	CcSEcCtD
Galantamine—Body temperature increased—Methotrexate—multiple sclerosis	8.7e-05	0.00049	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	8.67e-05	0.00266	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	8.56e-05	0.00263	CbGpPWpGaD
Galantamine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	8.51e-05	0.00261	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IFNG—multiple sclerosis	8.4e-05	0.00258	CbGpPWpGaD
Galantamine—Vomiting—Prednisone—multiple sclerosis	8.37e-05	0.000472	CcSEcCtD
Galantamine—Rash—Prednisone—multiple sclerosis	8.3e-05	0.000468	CcSEcCtD
Galantamine—Dermatitis—Prednisone—multiple sclerosis	8.29e-05	0.000467	CcSEcCtD
Galantamine—Headache—Prednisone—multiple sclerosis	8.25e-05	0.000465	CcSEcCtD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	8.18e-05	0.00251	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	8.11e-05	0.00249	CbGpPWpGaD
Galantamine—Hypersensitivity—Methotrexate—multiple sclerosis	8.11e-05	0.000457	CcSEcCtD
Galantamine—CHRNA4—Neuronal System—BCHE—multiple sclerosis	7.91e-05	0.00243	CbGpPWpGaD
Galantamine—Asthenia—Methotrexate—multiple sclerosis	7.9e-05	0.000445	CcSEcCtD
Galantamine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	7.83e-05	0.0024	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	7.83e-05	0.0024	CbGpPWpGaD
Galantamine—Nausea—Prednisone—multiple sclerosis	7.82e-05	0.000441	CcSEcCtD
Galantamine—CHRNG—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	7.74e-05	0.00238	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.72e-05	0.00237	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.72e-05	0.00237	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—POMC—multiple sclerosis	7.54e-05	0.00232	CbGpPWpGaD
Galantamine—Diarrhoea—Methotrexate—multiple sclerosis	7.53e-05	0.000424	CcSEcCtD
Galantamine—CHRNA9—Neuronal System—MAPK1—multiple sclerosis	7.5e-05	0.0023	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—BCHE—multiple sclerosis	7.36e-05	0.00226	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.33e-05	0.00225	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.33e-05	0.00225	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.29e-05	0.00224	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	7.28e-05	0.00224	CbGpPWpGaD
Galantamine—Dizziness—Methotrexate—multiple sclerosis	7.28e-05	0.00041	CcSEcCtD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	7.2e-05	0.00221	CbGpPWpGaD
Galantamine—Vomiting—Methotrexate—multiple sclerosis	7e-05	0.000394	CcSEcCtD
Galantamine—Rash—Methotrexate—multiple sclerosis	6.94e-05	0.000391	CcSEcCtD
Galantamine—Dermatitis—Methotrexate—multiple sclerosis	6.93e-05	0.000391	CcSEcCtD
Galantamine—Headache—Methotrexate—multiple sclerosis	6.89e-05	0.000388	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	6.82e-05	0.0021	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—POMC—multiple sclerosis	6.73e-05	0.00207	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—MAPK1—multiple sclerosis	6.56e-05	0.00201	CbGpPWpGaD
Galantamine—Nausea—Methotrexate—multiple sclerosis	6.54e-05	0.000368	CcSEcCtD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.54e-05	0.00201	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.54e-05	0.00201	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—multiple sclerosis	6.29e-05	0.00193	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—MAPK1—multiple sclerosis	6.22e-05	0.00191	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	6.15e-05	0.00189	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.12e-05	0.00188	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—MAPK1—multiple sclerosis	5.93e-05	0.00182	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	5.92e-05	0.00182	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.85e-05	0.0018	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	5.73e-05	0.00176	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—MAPK1—multiple sclerosis	5.71e-05	0.00175	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	5.67e-05	0.00174	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—BCHE—multiple sclerosis	5.64e-05	0.00173	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—MAPK1—multiple sclerosis	5.58e-05	0.00171	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	5.41e-05	0.00166	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	5.19e-05	0.00159	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—SLC30A7—multiple sclerosis	5.16e-05	0.00159	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	5.12e-05	0.00157	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	5.12e-05	0.00157	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	5.07e-05	0.00156	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.05e-05	0.00155	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.05e-05	0.00155	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	5.01e-05	0.00154	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.95e-05	0.00152	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	4.92e-05	0.00151	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	4.87e-05	0.0015	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	4.83e-05	0.00148	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—MAPK1—multiple sclerosis	4.71e-05	0.00145	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SRM—multiple sclerosis	4.63e-05	0.00142	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	4.63e-05	0.00142	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—SLC30A7—multiple sclerosis	4.6e-05	0.00141	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IL6—multiple sclerosis	4.39e-05	0.00135	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	4.31e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.3e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	4.26e-05	0.00131	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—PABPC1—multiple sclerosis	4.17e-05	0.00128	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—MAPK1—multiple sclerosis	4.15e-05	0.00127	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—IL6—multiple sclerosis	4.14e-05	0.00127	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SRM—multiple sclerosis	4.13e-05	0.00127	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.09e-05	0.00126	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	4.01e-05	0.00123	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	4e-05	0.00123	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.9e-05	0.0012	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPL5—multiple sclerosis	3.76e-05	0.00116	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—PABPC1—multiple sclerosis	3.72e-05	0.00114	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.7e-05	0.00114	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.66e-05	0.00112	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	3.5e-05	0.00108	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.48e-05	0.00107	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.47e-05	0.00107	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPL5—multiple sclerosis	3.36e-05	0.00103	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.31e-05	0.00102	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—MAPK1—multiple sclerosis	3.3e-05	0.00101	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—MAPK1—multiple sclerosis	3.27e-05	0.001	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP27B1—multiple sclerosis	3.26e-05	0.001	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP24A1—multiple sclerosis	3.26e-05	0.001	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.19e-05	0.00098	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.02e-05	0.000926	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—MAPK1—multiple sclerosis	2.99e-05	0.000917	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPC5—multiple sclerosis	2.98e-05	0.000917	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP27B1—multiple sclerosis	2.91e-05	0.000894	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP24A1—multiple sclerosis	2.91e-05	0.000894	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—MAPK1—multiple sclerosis	2.83e-05	0.000871	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	2.83e-05	0.000868	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—MAPK1—multiple sclerosis	2.81e-05	0.000862	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—BCHE—multiple sclerosis	2.76e-05	0.000846	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.67e-05	0.000821	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—MAPK1—multiple sclerosis	2.66e-05	0.000819	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPC5—multiple sclerosis	2.66e-05	0.000818	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RRM1—multiple sclerosis	2.47e-05	0.00076	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—MAPK1—multiple sclerosis	2.31e-05	0.00071	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.28e-05	0.000701	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.28e-05	0.000699	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.23e-05	0.000686	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RRM1—multiple sclerosis	2.21e-05	0.000678	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.17e-05	0.000666	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.15e-05	0.000661	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.13e-05	0.000653	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	1.92e-05	0.000589	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.92e-05	0.000589	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SRM—multiple sclerosis	1.9e-05	0.000583	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.76e-05	0.000541	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.71e-05	0.000526	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—MAPK1—multiple sclerosis	1.65e-05	0.000506	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.65e-05	0.000506	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.5e-05	0.000462	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—MAPK1—multiple sclerosis	1.47e-05	0.000452	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.47e-05	0.000452	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—POMC—multiple sclerosis	1.42e-05	0.000437	CbGpPWpGaD
Galantamine—ACHE—Metabolism—BCHE—multiple sclerosis	1.42e-05	0.000436	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CCL2—multiple sclerosis	1.39e-05	0.000428	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.34e-05	0.000412	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.34e-05	0.000411	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.34e-05	0.000411	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—POMC—multiple sclerosis	1.27e-05	0.00039	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CCL2—multiple sclerosis	1.24e-05	0.000382	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.24e-05	0.000381	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.22e-05	0.000376	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.15e-05	0.000354	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.01e-05	0.000312	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	8.75e-06	0.000269	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	8.75e-06	0.000269	CbGpPWpGaD
Galantamine—ACHE—Metabolism—APOE—multiple sclerosis	8.54e-06	0.000262	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPC5—multiple sclerosis	8e-06	0.000246	CbGpPWpGaD
Galantamine—BCHE—Metabolism—APOE—multiple sclerosis	7.62e-06	0.000234	CbGpPWpGaD
Galantamine—ACHE—Metabolism—POMC—multiple sclerosis	7.34e-06	0.000225	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ALB—multiple sclerosis	6.69e-06	0.000206	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.63e-06	0.000204	CbGpPWpGaD
Galantamine—BCHE—Metabolism—POMC—multiple sclerosis	6.55e-06	0.000201	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ALB—multiple sclerosis	5.97e-06	0.000183	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.83e-06	0.000179	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.81e-06	0.000117	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—APOE—multiple sclerosis	3.5e-06	0.000108	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—POMC—multiple sclerosis	3.01e-06	9.25e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ALB—multiple sclerosis	2.74e-06	8.43e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.29e-06	7.04e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—POMC—multiple sclerosis	1.97e-06	6.05e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ALB—multiple sclerosis	1.79e-06	5.51e-05	CbGpPWpGaD
